NAV

Dinutuximab

Identification

Summary

Dinutuximabis an immunotherapeutic agent used in combination with other immunomodulating agents to treat high-risk neuroblastoma in pediatric patients who achieve at least a partial response to prior first-line multiagent, multimodality therapy.

Brand Names
Unituxin
Generic Name
Dinutuximab
DrugBank Accession Number
DB09077
Background

Dinutuximab IgG1单克隆human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour. It is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Protein Chemical Formula
C6422H9982N1722O2008S48
Protein Average Weight
145000.0 Da
Sequences
不可用
Synonyms
  • Dinutuximab
  • Dinutuximab beta
  • Monoclonal antibody ch14.18
External IDs
  • APN-311
  • APN311
  • ch14.18
  • ch14.18-UTC

Pharmacology

Indication

Dinutuximab is indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy. Despite a high clinical response seen after first-line treatment, the complete eradication of neuroblastoma is rarely achieved and the majority of patients with advanced disease suffer a relapse. Current strategies for treatment include immunotherapy with drugs such as dinutuximab to target surviving neuroblastoma cells and to prevent relapse.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information oncontraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

In vitro dinutuximab binds to neuroblastoma tumour cells and mediates the lysis of tumour cells via cell-mediated and complement-mediated cytotoxicity.

Mechanism of action

Dinutuximab IgG1单克隆human/mouse chimeric antibody against GD2, a disialoganglioside expressed on tumors of neuroectodermal origin, including human neuroblastoma and melanoma, with highly restricted expression on normal tissues. It is composed of the variable heavy- and light-chain regions of the murine anti-GD2 mAb 14.18 and the constant regions of human IgG1 heavy-chain and kappa light-chain. By binding to GD2, dinutiximab induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity of tumor cells thereby leading to apoptosis and inhibiting proliferation of the tumour.

Target Actions Organism
AGD2 disialoganglioside
inhibitor
 Humans
Absorption

不可用

Volume of distribution

The mean volume of distribution at steady state (Vdss) is 5.4 L

Protein binding

不可用

Metabolism
不可用
Route of elimination

不可用

Half-life

The terminal half-life is 10 days

Clearance

The clearance is 0.21 L/day and increases with body size

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including:blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

The most common (incidence 15 %) grade 3 or 4 treatment-related adverse events in dinutuximab compared with standard therapy recipients were neuropathic pain (52 vs. 6 %), fever without neutropenia (39 vs. 6 %), any in-fection (39 vs. 22 %), hypokalaemia (35 vs. 2 %), hypersensitivity reactions (25 vs. 1 %), hyponatraemia (23 vs. 4 %), elevation of alanine transferase levels (23 vs. 3 %) and hypotension (18 vs. 0 %). Based on its mechanism of action, dinutuximab may cause fetal harm when administered to a pregnant woman however, there are no studies in pregnant women and no reproductive studies in animals to inform the drug-associated risk. Non-clinical studies suggest that dinutuximab-induced neuropathic pain is mediated by binding of the antibody to the GD2 antigen located on the surface of peripheral nerve fibers and myelin and subsequent induction of cell- and complement-mediated cytotoxicity. In clinical trials, 114 (85%) patients treated in the dinutuximab/RA group experienced pain despite pre-treatment with analgesics including morphine sulfate infusion. Severe (Grade 3) pain occurred in 68 (51%) patients in the dinutuximab/RA group compared to 5 (5%) patients in the RA group. Pain typically occurred during the dinutuximab infusion and was most commonly reported as abdominal pain, generalized pain, extremity pain, back pain, neuralgia, musculoskeletal chest pain, and arthralgia.

Pathways
不可用
Pharmacogenomic Effects/ADRsBrowse all" title="" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
不可用

Interactions

Drug InteractionsLearn More" title="" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction
Integrate drug-drug
interactions in your software
Abaloparatide The risk or severity of adverse effects can be increased when Abaloparatide is combined with Dinutuximab.
Abatacept The risk or severity of adverse effects can be increased when Abatacept is combined with Dinutuximab.
Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Dinutuximab.
Acebutolol The risk or severity of adverse effects can be increased when Acebutolol is combined with Dinutuximab.
Acenocoumarol The risk or severity of bleeding can be increased when Acenocoumarol is combined with Dinutuximab.
Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Dinutuximab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Dinutuximab.
Adenovirus type 7 vaccine live The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Dinutuximab.
Aducanumab The risk or severity of adverse effects can be increased when Dinutuximab is combined with Aducanumab.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Dinutuximab.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
No interactions found.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
药品信息的访问over 10 global regions.
Access now
Brand Name Prescription Products
Name Dosage 强度 Route Labeller Marketing Start Marketing End Region Image
Qarziba Injection, solution, concentrate 4.5 mg/ml Intravenous Eusa Pharma (Netherlands) Bv 2020-12-16 Not applicable EU flag
Unituxin Injection 3.5 mg/1mL Intravenous United Therapeutics Corporation 2015-03-10 Not applicable US flag
Unituxin Injection, solution, concentrate 3.5 mg/ml Intravenous United Therapeutics Europe Ltd 2021-01-12 2017-04-28 EU flag
Unituxin Solution 3.5 mg / mL Intravenous United Therapeutics Corporation 2019-05-01 Not applicable Canada flag

Categories

ATC Codes
L01FX06 — Dinutuximab beta
Drug Categories
Chemical TaxonomyProvided byClassyfire
Description
不可用
Kingdom
Organic Compounds
Super Class
Organic Acids
Class
Carboxylic Acids and Derivatives
Sub Class
Amino Acids, Peptides, and Analogues
Direct Parent
Peptides
Alternative Parents
不可用
Substituents
不可用
Molecular Framework
不可用
External Descriptors
不可用
Affected organisms
不可用

Chemical Identifiers

UNII
7SQY4ZUD30
CAS number
1363687-32-4

References

General References
  1. Dhillon S: Dinutuximab: first global approval. Drugs. 2015 May;75(8):923-7. doi: 10.1007/s40265-015-0399-5. [Article]
  2. Ahmed M, Cheung NK: Engineering anti-GD2 monoclonal antibodies for cancer immunotherapy. FEBS Lett. 2014 Jan 21;588(2):288-97. doi: 10.1016/j.febslet.2013.11.030. Epub 2013 Dec 1. [Article]
  3. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA: Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res. 1991 Jan 1;51(1):144-9. [Article]
  4. Aixinjueluo W, Furukawa K, Zhang Q, Hamamura K, Tokuda N, Yoshida S, Ueda R, Furukawa K: Mechanisms for the apoptosis of small cell lung cancer cells induced by anti-GD2 monoclonal antibodies: roles of anoikis. J Biol Chem. 2005 Aug 19;280(33):29828-36. Epub 2005 May 26. [Article]
KEGG Drug
D10559
PubChem Substance
347910402
RxNav
1606274
ChEMBL
CHEMBL3137342
Drugs.com
Drugs.com Drug Page
Wikipedia
Dinutuximab
FDA label
Download (446 KB)

Clinical Trials

Clinical TrialsLearn More" title="" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
4 Not Yet Recruiting Treatment Neuroblastoma (NB) 1
3 Active Not Recruiting Treatment Localized, resectable Neuroblastoma (NB)/Localized, unresectable Neuroblastoma (NB)/Recurrent Neuroblastoma/Regional Neuroblastoma/Stage 4 Neuroblastoma/Stage 4S Neuroblastoma 1
3 Completed Treatment High Risk Neuroblastoma 1
3 Recruiting Treatment High Risk Neuroblastoma 1
3 Recruiting Treatment Neuroblastoma (NB) 1
3 Unknown Status Treatment Neuroblastoma (NB) 1
2 Active Not Recruiting Treatment Ganglioneuroblastoma/High Risk Neuroblastoma 1
2 Active Not Recruiting Treatment Neuroblastoma (NB) 3
2 Completed Treatment Ganglioneuroblastoma/Recurrent Neuroblastoma 1
2 Not Yet Recruiting Treatment Childhood Osteosarcoma 1

Pharmacoeconomics

Manufacturers
不可用
Packagers
不可用
Dosage Forms
Form Route 强度
Injection, solution, concentrate Intravenous 4.5 mg/ml
Injection, solution, concentrate Intravenous; Parenteral 4.5 MG/ML
Injection Intravenous 3.5 mg/1mL
Injection, solution, concentrate Intravenous 3.5 MG/ML
Solution Intravenous 3.5 mg / mL
Prices
不可用
Patents
Patent Number Pediatric Extension Approved Expires (estimated) Region
US20140170155 No 2014-02-18 2038-02-18 US flag

Properties

State
Solid
Experimental Properties
不可用

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets tounlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details 1.GD2 disialoganglioside
Kind
Small molecule
Organism
Humans
Pharmacological action
Yes
Actions
Inhibitor
GD2 is a disialoganglioside that is overexpressed on neuroblastoma cells and other cells of neuroectodermal origin, including the central nervous system and peripheral nerves.
References
  1. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA: Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res. 1991 Jan 1;51(1):144-9. [Article]

Drug created at June 18, 2015 17:47 / Updated at December 06, 2022 13:40